Immunology Investor Event

Dupixent: Chronic Obstructive Pulmonary Disease Number of patients (thousands) Prevalence 10,052 10,753 2,084 22,889 Treated 8,367 8,700 1,473 18,540 GOLD D 1,581 1,222 207 3,010 Eosinophilic population 300 200 50 550 нн 0 2,000 10,000 18,000 20,000 22,000 24,000 US Europe (1) Japan Source: Sanofi analysis sanofi COPD with eosinophilic phenotype uncontrolled with current SoC (patients that are on triple therapy among GOLD D) SoC: Standard of Care; GOLD criteria: Global Initiative for Chronic Obstructive Lung Disease - Group D: high risk (≥2 exacerbations/year, or one+ requiring hospitalization) and more symptoms (mMRC≥ 2 or CAT≥ 10) (1) Germany, France, Italy, Spain & United Kingdom 8 Immunology Investor Event

View entire presentation